Rapid epigenomic classification of acute leukemia

Acute leukemia (AL) is an aggressive blood cancer that requires precise molecular classification and urgent treatment. However, standard-of-care diagnostic tests are time and resource intensive and may not resolve the full spectrum of AL disease heterogeneity.

In this presentation, Dr. Griffin discusses recent efforts to use Oxford Nanopore sequencing and machine learning to rapidly classify AL solely on the basis of epigenomic (DNA methylation) information.

Biography

Dr. Griffin is Assistant Professor of Pathology at Harvard Medical School, Principal Investigator in the Department of Pathology at Dana-Farber Cancer Institute, and Associate Pathologist in Hematopathology and Molecular Pathology at the Brigham and Women's Hospital. Dr. Griffin completed his undergraduate and medical studies at Duke University, clinical training at the Brigham and Women's Hospital, and post-doctoral studies in cancer epigenomics at the Broad Institute of MIT and Harvard.

Please note: This is independent, investigator-led research using Oxford Nanopore technology. Oxford Nanopore products are for research use only, and not for use in diagnostic procedures.